89Zr-bevacizumab PET Imaging in Patients With Renal Cell Carcinoma Treated With Sunitinib or Bevacizumab Plus Interferon; a Pilot Study
- To explore if 89Zr-bevacizumab PET imaging can differentiate RCC patients with
progressive disease from patients with non-progressive disease during treatment with
sunitinib or bevacizumab plus interferon.
- To explore relationships between VEGF pathway related biomarkers and 89Zr-bevacizumab
- To explore effect of 2 weeks off treatment in the sunitinib arm on pharmacodynamic
biomarkers and 89Zr-bevacizumab PET response.
Observational Model: Cohort, Time Perspective: Prospective
The primary endpoint is the change in SUV between baseline 89Zr-bevacizumab PET scan and the scan performed after 2 and 6 weeks of treatment with sunitinib or bevacizumab plus interferon in patients with RCC.
after 2 and 6 weeks
Sjoukje F. Oosting, MD
University Medical Centre Groningen
Netherlands: Medical Ethics Review Committee (METC)